TSPYL5 and lung cancer: The degradation of p53 associated with the formation of the TSPYL5/USP7 complex has also been demonstrated in lung cancer cells that overexpress one of the potential regulators of TSPYL5–MUC16, which likely induces resistance to cisplatin and gemcitabine in this cell type [10].